Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28904611 | 0.78 | — | — | |
| SCHEMBL13715066 | 0.67 | ARG1 (0.34) | ARG1ARG2 | |
| SCHEMBL8016763 | 0.67 | ARG1 (0.34) | ARG1ARG2 | |
| SCHEMBL1818488 | 0.63 | AKR1C1 (0.37) | — | |
| SCHEMBL23884534 | 0.63 | AKR1C1 (0.37) | — | |
| SCHEMBL13715084 | 0.62 | ARG1 (0.30) | ARG1ARG2 | |
| SCHEMBL7981038 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL4684924 | 0.62 | ARG1 (0.47) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL30382824 | 0.62 | ARG1 (0.47) | ARG1ARG2 | |
| SCHEMBL11239413 | 0.61 | LMNA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2024-04-25 | — | — | US | disclosed |
| EP-4291192-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | Neuren Pharmaceuticals Limited (NZ) | 2023-12-20 | — | — | EP | disclosed |
| US-20150258091-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-09-17 | — | — | US | disclosed |
| US-9119851-B2 | Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals | NEUREN PHARMACEUTICALS, LTD. (NZ) | 2015-09-01 | — | — | US | disclosed |
| US-20140309230-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-10-16 | — | — | US | disclosed |
| US-8791117-B2 | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-07-29 | — | — | US | disclosed |
| US-8519127-B2 | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy | NEUREN PHARMACEUTICALS LIMITED (AU) | 2013-08-27 | — | — | US | disclosed |
| US-20110201614-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-08-18 | — | — | US | disclosed |
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-03-03 | — | — | US | disclosed |
| US-20090263334-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | BICKERDIKE MIKE JOHN | 2009-10-22 | — | — | US | disclosed |
| WO-2008063311-A2 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | PMP22, IAPP, GCG | ARG1 2600/4885ARG2 678/4885 |
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | COMT, HSD17B3, HSD3B1 | ARG1 3293/4885ARG2 3099/4885 |
| US-20110201614-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | GRIA2, QPCT, GRM2 | ARG1 723/4885ARG2 226/4885 |
| US-20090263334-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | GRIA2, QPCT, GRM2 | ARG1 723/4885ARG2 226/4885 |
| US-20140309230-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | GRIA2, QPCT, GRM2 | ARG1 723/4885ARG2 226/4885 |
| US-20150258091-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | GRIA2, GRIN2A, QPCT | ARG1 1043/4885ARG2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.